A61K 51/0482
Chelates from cyclic ligands
Official title: {chelates from cyclic ligands, e.g. DOTA}
A61K51/0482 (Chelates from cyclic ligands) appears on 394 US grants and 631 published applications in this corpus.
Search patents in A61K- Granted patents
- 394
- Published applications
- 631
- Assignees
- 312
- Inventors
- 1,174
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 0 | 0 |
| 1993 | 4 | 0 |
| 1994 | 10 | 0 |
| 1995 | 11 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 6 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 9 |
| 2003 | 7 | 6 |
| 2004 | 4 | 10 |
| 2005 | 6 | 10 |
| 2006 | 5 | 2 |
| 2007 | 4 | 8 |
| 2008 | 8 | 5 |
| 2009 | 2 | 8 |
| 2010 | 4 | 5 |
| 2011 | 0 | 10 |
| 2012 | 4 | 10 |
| 2013 | 8 | 9 |
| 2014 | 9 | 28 |
| 2015 | 12 | 18 |
| 2016 | 19 | 28 |
| 2017 | 9 | 19 |
| 2018 | 14 | 17 |
| 2019 | 13 | 29 |
| 2020 | 25 | 45 |
| 2021 | 31 | 57 |
| 2022 | 27 | 74 |
| 2023 | 24 | 49 |
| 2024 | 33 | 59 |
| 2025 | 40 | 62 |
| 2026 | 26 | 54 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition containing buffer6 Oct 2026US 12,752,008 B2Perseus Proteomics Inc.
- Purification process for the preparation of non-carrier added copper-6429 Sep 2026US 12,749,589 B2Curium US LLC
- Urokinase plasminogen activator receptor-targeted radiopharmaceutical22 Sep 2026US 12,741,039 B2Monopar Therapeutics Inc.
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer22 Sep 2026US 12,741,964 B2Cornell University
- Radioligands for pretargeted PET imaging and methods of their therapeutic use15 Sep 2026US 12,734,258 B2Memorial Sloan Kettering Cancer Center
- Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents8 Oct 2026US 2026/0306634 A1Wisconsin Alumni Research Foundation
- Cleavable radioligands for targeting cell surface receptors and uses thereof1 Oct 2026US 2026/0295099 A1Full-Life Technologies UK Limited
- Fap-activated radiotheranostics and uses related thereto24 Sep 2026US 2026/0284235 A1Trustees of Tufts College
- Methods for reducing and/or preventing de-chelation of a chelated radioisotope24 Sep 2026US 2026/0284236 A1Curadel Surgical Innovations, Inc.
- Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof24 Sep 2026US 2026/0284243 A1Alpha-9 Oncology, Inc.
Most cited
By later US patents
- 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs191US 4,885,363 AE. R. Squibb & Sons, Inc. · 1989
- Macrocyclic bifunctional chelating agents128US 4,678,667 A501 Regents of the University of California · 1987
- Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs79US 6,143,274 A2000
- Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs75US 5,474,756 ABracco International B. V. · 1995
- Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs64US 5,846,519 ABracco Diagnostics Inc. · 1998